Alzheimer’s clinical trial recruitment: What we learned from over 2,000 patients [whitepaper]

Though it normally begins with mild memory loss, Alzheimer’s disease is a progressive condition that will eventually develop into a severely life-altering affliction. Alzheimer’s disease is the most common type of dementia, estimated to impact more than 6 million Americans, most of whom are over the age of 65.

Despite its prevalence, scientists do not fully understand the cause of Alzheimer’s disease and have not developed a cure. There is also no way to definitively diagnose Alzheimer’s, meaning that individuals often endure multiple assessments and testing before they can receive proper treatment and care. Additionally, many individuals are not able to manage this process on their own — a number of individuals with Alzheimer’s are cared for by a family member, which can lead to practical, financial, and emotional burdens that care providers must shoulder.

For all of these reasons, successful research is key to improving the lives of those impacted by Alzheimer’s — but this can only happen when patients and their caregivers can access the wide breadth of actively recruiting studies. For this in-depth whitepaper, we surveyed over 2,000 of these patients and their caregivers to learn more about the impact that Alzheimer’s disease has. With this information, we’re able to make clear recommendations on how clinical researchers can best engage with potential participants for studies that can lead to medical breakthroughs. Click the button below to get a free download.